OverviewSuggest Edit

Harpoon Therapeutics is an immuno-oncology company which uses a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. The Company has designed a novel antibody-based drug discovery platform called TriTAC™ that unleashes the target cell killing properties of a patient’s own immune system through T cell activation.

TriTAC™ antibodies are designed to simultaneously bind to cancer cells and T cells, causing the attached T cells to release toxic factors leading to destruction of the attached target cell. In addition, TriTAC™ antibodies are engineered to bind to human serum albumin which allows for less frequent dosing, and their relatively small size allows for improved penetration into tumor tissue.

TypePublic
Founded2015
HQSouth San Francisco, CA, US
Websiteharpoontx.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Feb 2019)45
Job Openings11
Revenue (FY, 2017)$708 K
Share Price (May 2022)$1.8(-15%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Harpoon Therapeutics

Julie Eastland

Julie Eastland

President and Chief Executive Officer
Natalie R. Sacks

Natalie R. Sacks

Chief Medical Officer
Susan Dana Jones

Susan Dana Jones

Senior Vice President, Product Development
Rick Austin

Rick Austin

Vice President, Research
Holger Wesche

Holger Wesche

Chief Scientific Officer
Georgia L. Erbez

Georgia L. Erbez

Chief Financial Officer
Show more

Harpoon Therapeutics Office Locations

Harpoon Therapeutics has offices in South San Francisco and Louisville
South San Francisco, CA, US (HQ)
4000 Shoreline Ct #250
Louisville, KY, US
462 S 4th St
South San Francisco, CA, US
131 Oyster Point Blvd #300
Show all (3)

Harpoon Therapeutics Financials and Metrics

Harpoon Therapeutics Revenue

Harpoon Therapeutics's revenue was reported to be $708 k in FY, 2017
USD

Market capitalization (11-May-2022)

69.5m

Closing stock price (11-May-2022)

1.8

Cash (31-Dec-2020)

21.2m

EV

61.8m
Harpoon Therapeutics's current market capitalization is $69.5 m.
USDFY, 2016FY, 2017

Revenue

708.0k

General and administrative expense

3.4m3.6m

R&D expense

7.8m13.6m

Operating expense total

11.1m17.2m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

985.0k29.4m89.5m88.7m21.2m

Prepaid Expenses

559.0k224.0k730.0k2.5m3.7m

Current Assets

8.3m29.6m90.2m150.6m129.8m

PP&E

90.0k2.1m3.0m11.4m10.2m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

27.9m95.9m52.1m56.8m36.2m34.7m22.7m

Prepaid Expenses

1.1m2.1m3.4m1.8m5.6m3.2m2.9m

Current Assets

28.9m140.7m137.3m123.0m128.7m174.8m157.7m

PP&E

2.3m5.5m11.8m11.8m11.0m10.8m10.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.4m)(16.8m)(27.4m)(55.6m)(49.9m)

Depreciation and Amortization

198.0k366.0k644.0k900.0k2.1m

Accounts Payable

570.0k804.0k2.6m(1.8m)(1.2m)

Cash From Operating Activities

(10.8m)1.7m(27.1m)(2.9m)(8.6m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(11.9m)(17.6m)(13.6m)(25.4m)(41.3m)(12.6m)(25.2m)(38.6m)

Depreciation and Amortization

244.0k447.0k297.0k596.0k400.0k503.0k1.0m1.5m

Accounts Payable

(12.0k)(10.0k)(771.0k)(876.0k)(697.0k)(1.1m)(1.0m)(815.0k)

Cash From Operating Activities

(10.9m)(20.7m)(12.4m)(25.4m)(36.6m)(17.5m)20.0m6.6m
USDFY, 2016

Financial Leverage

1.9 x
Show all financial metrics

Harpoon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Harpoon Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Harpoon Therapeutics Online and Social Media Presence

Embed Graph

Harpoon Therapeutics News and Updates

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

HPN328, Harpoon’s DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer HPN328, Harpoon’s DLL3-targeting T cell engager, to be evaluated in combination with anti-PD-L1 antibody in patients with small cell lung cancer

Harpoon Therapeutics Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index TriTAC-XR demonstrates extended release mechanism that confirms accumulation of active drug which improves therapeutic index

Harpoon Therapeutics Announces Leadership Change

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that Natalie Sacks, M.D., Chief Medical Officer, will be leaving the company effective June 1, 2022. D…

Harpoon Therapeutics to Participate in Canaccord Genuity Horizons in Oncology Virtual Conference

SOUTH SAN FRANCISCO, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virt…

Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN328, a del…

Harpoon Therapeutics Provides Pipeline Development Milestones for 2022

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a pipeline milestone update on its TriTAC development programs.
Show more

Harpoon Therapeutics Blogs

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update Content Import Thu, 05/12/2022 - 16:05 Harpoon Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update May 12, 2022 Earnings …

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Content Import Thu, 03/10/2022 - 16:06 Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update March 10, 2022…

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

SOUTH SAN FRANCISCO, Calif. , March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HPN217, a

Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

Preclinical data demonstrates that extended-release TriTAC-XR T cell engager platform could mitigate toxicities, such as cytokine release syndrome SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate

Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that management will participate in two upcoming virtual investor conferences: A fireside
Show more

Harpoon Therapeutics Frequently Asked Questions

  • When was Harpoon Therapeutics founded?

    Harpoon Therapeutics was founded in 2015.

  • Who are Harpoon Therapeutics key executives?

    Harpoon Therapeutics's key executives are Julie Eastland, Natalie R. Sacks and Susan Dana Jones.

  • How many employees does Harpoon Therapeutics have?

    Harpoon Therapeutics has 45 employees.

  • Who are Harpoon Therapeutics competitors?

    Competitors of Harpoon Therapeutics include Enara Bio, Aeglea and ImmunoGen.

  • Where is Harpoon Therapeutics headquarters?

    Harpoon Therapeutics headquarters is located at 4000 Shoreline Ct #250, South San Francisco.

  • Where are Harpoon Therapeutics offices?

    Harpoon Therapeutics has offices in South San Francisco and Louisville.

  • How many offices does Harpoon Therapeutics have?

    Harpoon Therapeutics has 3 offices.